JYJia Yin

Jia Yin

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Jia Yin has a total of 208 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Are We Doing Better a Decade Later?

    by In Young Chung, Rachel Y. Chen, Kyong Min Lee, Cara Knasel, Chhavi Saini, Eric Wang, Alja Crnej, James Chodosh, Joseph B. Ciolino, Teresa C. Chen, et al.

  • Open Access

    An intraocular oxygenated emulsion suppresses retinal fibrosis by inhibiting hypoxia-driven bioenergetic shifts and mesenchymal transformation

    by Yihe Chen, Binapani Mahaling, Lei Xi, Qiaoran Qi, Maryam Shayan, Anil Upreti, Zhirong Lin, Asmaa Zidan, Qiurong Zhu, Olivia Qin, et al.

    Fibrosis drives progressive organ dysfunction, yet targeted therapies remain limited. In the eye, proliferative vitreoretinopathy (PVR) is a blinding fibrotic disease without approved medical treatment. Here, single-cell RNA sequencing of human PVR membranes revealed convergent activation of hypoxia-responsive programs across major cell populations. Using a molecular probe, we directly validated spatial and temporal hypoxia in an open-globe injury model that recapitulates traumatic PVR. Intravitreal delivery of a supersaturated oxygen emulsion (SSOE) preserved retinal function while reducing fibrocellular membrane formation and inflammation. Mechanistically, human PVR cells exhibited metabolic shifts toward glycolysis alongside epithelial-mesenchymal transition (EMT). SSOE corrected cellular hypoxia, preserved mitochondrial integrity, suppressed glycolytic shift, and inhibited EMT in human retinal pigment epithelial cells, while reducing spontaneous contractility in primary human PVR cell cultures. Together, these findings identify hypoxia as a critical driver of retinal fibrosis and support localized intraocular oxygenation as a viable therapeutic strategy for preventing fibrotic vision loss.

  • Symptoms of Small Fiber Neuropathy in Patients With Dry Eye Disease

    by Asmaa A. Zidan, Jordan Dean, Zhirong Lin, Ahmad Kheirkhah, Reza Dana, Jae Young You, Anne Louise Oaklander, Jia Yin

    Purpose: Small fiber neuropathy (SFN) is a neurologic condition affecting small-diameter nerve fibers, including those innervating the ocular surface. In this study, we aim to assess the prevalence and characteristics of SFN symptoms in patients with dry eye disease (DED). Methods: This was a prospective study conducted at 2 academic eye centers. DED symptoms were assessed using the Ocular Surface Disease Index (OSDI) questionnaire, and adult patients with an OSDI score ≥13 and a clinical diagnosis of DED at Mass Eye and Ear and Beth Israel Deaconess Medical Center were included in the study. Ocular pain was assessed using the Ocular Pain Assessment Survey (OPAS). SFN symptoms were measured using validated Small-Fiber Symptom Survey (SSS) questionnaire, with scores ≥32.5 considered abnormal. DED signs including corneal fluorescein staining (CFS), tear breakup time (TBUT), tear production, and corneal sensitivity were assessed. Patients received standard DED treatments, and their responses were reassessed after 6 to 12 months. Results: Among 31 participants with DED (23–87 years, 80.6% female), 38.7% had abnormal SSS scores. SSS scores correlated with DED symptoms (r = 0.43 P = 0.017) and ocular pain (r = 0.62 P = 0.0003); correlated negatively with CFS (r = −0.42 P = 0.018); and did not correlate with TBUT, tear production, or corneal sensitivity. Despite standard treatments and stable clinical signs, most patients with severe SFN symptoms reported worsening dry eye symptoms in follow-up. Conclusions: This study demonstrates that SFN symptoms were prevalent in DED population and positively correlated with ocular pain and dry eye symptoms and negatively with CFS. Patients with severe SFN symptoms reported less favorable responses to standard dry eye treatments.

  • Open Access

    Calcitonin Gene-Related Peptide Ameliorates Experimental Dry Eye Disease

    by Zhirong Lin, Bhupender Verma, Shuyan Zhu, Asmaa A. Zidan, Sheyda Najafi, Amirreza Naderi, Elsayed Elbasiony, Jia Yin

    Calcitonin gene-related peptide (CGRP) level is reduced in the tears of patients with dry eye disease (DED). The current study aims to investigate the expression and therapeutic potential of CGRP as topical eye drops in treating experimental DED. Human corneal epithelial cells (CECs) were cultured under hyperosmotic stress (HS) and the effects of CGRP on cell viability, proliferation, migration, and apoptosis were determined in vitro. The expression of CGRP in the cornea and trigeminal ganglion (TG) of desiccating stress-induced experimental DED mice was determined. CGRP or albumin control were topically applied thrice daily for two weeks in DED mice and DED parameters were assessed clinically. Cornea and conjunctiva were collected separately after treatment, and cell proliferation and tissue inflammation were determined using immunostaining and flow cytometry. Experimental DED mice showed significantly reduced CGRP mRNA and protein expression in their cornea and TG. CGRP promoted proliferation and downregulated apoptosis, TNF-α, IL-1β, and IL-6 mRNA levels during HS in cultured CECs. Clinically, topical application of CGRP significantly decreased corneal fluorescein staining score, increased tear break-up time, and preserved corneal epithelium in DED mice. In the cornea, CGRP significantly promoted epithelial proliferation and reduced infiltrating CD45+ leukocytes, and TNF-α and IL-1β expression in vivo. CGRP treatment did not significantly affect the frequency of CD45+ leukocytes in the conjunctiva. Our data demonstrate that CGRP expression in the cornea and TG is downregulated in DED. Topical CGRP treatment ameliorates DED severity by promoting epithelial proliferation and suppressing inflammation in the cornea.


  • Open Access

    Supersaturated Oxygen Emulsion Mitigates Hypoxia-Driven Corneal Neovascularization after Alkali Burn

    by Asmaa A. Zidan, Elsayed Elbasiony, Zhirong Lin, Sheyda Najafi, Kathryn Pate, Jia Yin


  • Neurotrophic Keratopathy in Pediatric Population: An IRIS® Registry Report

    by Asmaa A. Zidan, Joshua B. Gilbert, Eric A. Goldberg, Connor Ross, Tobias Elze, Alice C. Lorch, Joan W. Miller, Leyla Yavuz Saricay, Thomas Dohlman, Reza Dana, et al.


  • Top Cited Papers
    Open Access

    Cultivated autologous limbal epithelial cell (CALEC) transplantation for limbal stem cell deficiency: a phase I/II clinical trial of the first xenobiotic-free, serum-free, antibiotic-free manufacturing protocol developed in the US

    by Ula V. Jurkunas, Aaron R. Kaufman, Jia Yin, Allison Ayala, Maureen Maguire, Lassana Samarakoon, Lynette K. Johns, Mohit Parekh, Sanming Li, Alex Gauthier, et al.

    We developed a two-stage manufacturing process utilizing cultivated autologous limbal epithelial cells (CALEC), the first xenobiotic-free, serum-free, antibiotic-free protocol developed in the United States, to treat blindness caused by unilateral limbal stem cell deficiency (LSCD) and conducted a single-center, single-arm, phase I/II clinical trial. Primary outcomes were feasibility (meeting release criteria) and safety (ocular infection, corneal perforation, or graft detachment). Participant eligibility included male or female participants age 18 to <90 years old and ability to provide written informed consent with LSCD. Funding was provided by the National Eye Institute of the National Institutes of Health. CALEC grafts met release criteria in 14 (93%) of 15 participants at conclusion of trial. After first stage manufacturing, intracellular adenosine triphosphate levels correlated with colony forming efficiency (r = 0.65, 95% CI [0.04, 0.89]). One bacterial infection occurred unrelated to treatment, with no other primary safety events. The secondary outcome was to investigate efficacy based on improvement in corneal epithelial surface integrity (complete success) or improvement in corneal vascularization and/or participant symptomatology as measured by OSDI and SANDI (partial success). 86%, 93%, and 92% of grafts resulted in complete or partial success at 3, 12, and 18 months, respectively. Our results provide strong support that CALEC transplantation is safe and feasible and further studies are needed to evaluate therapeutic efficacy. Clinicaltrials.gov registration: NCT02592330.


  • Open Access

    Intracorneal hypopyon within a DSAEK graft

    by Angelica Piccini, Jia Yin, Levi N. Kanu

    Introduction: Intracorneal hypopyon is a rare condition involving the accumulation of inflammatory cells and debris within the structures of the cornea. We present an unusual case of an intracorneal hypopyon within a Descemet-stripping automated endothelial keratoplasty (DSAEK) graft. Patient and Clinical Findings: A 54-year-old woman status post DSAEK for bullous keratopathy secondary to prior trabeculectomy and cataract surgery developed a corneal ulcer. Corneal cultures grew Serratia marcescens, and topical antibiotics were given. Despite clinical improvement, a dense, deep corneal opacity with overlying epithelial defect persisted. Diagnosis, Intervention, and Outcomes: Anterior segment optical coherence tomography (AS-OCT) identified an intracorneal hypopyon between the Descemet membrane and corneal stroma of the DSAEK graft. Antibiotics were continued, while topical steroids, initially reduced in response to infection, were increased modestly. The patient's condition and hypopyon gradually improved. Conclusions: Ophthalmologists should consider the possibility of an intracorneal hypopyon masquerading as a persistent stromal infiltrate in the setting of infectious keratitis. Unlike unresponsive corneal infiltrates, intracorneal hypopyons may represent sterile inflammatory debris after resolved infection. AS-OCT was critical to distinguish the intracorneal hypopyon from a persistent infiltrate, which may have prevented unnecessary and/or invasive interventions.

  • Nerve Growth Factor Treatment for Neurotrophic Keratopathy in the IRIS® Registry

    by Asmaa A. Zidan, Joshua B. Gilbert, Eric Goldberg, Connor Ross, Tobias Elze, Alice C. Lorch, Joan W. Miller, Reza Dana, Jia Yin, Suzann Pershing, et al.


  • Primary Conjunctival Molluscum Contagiosum in a Patient With Ocular Graft-Versus-Host Disease

    by Asmaa A. Zidan, Aaron R. Kaufman, Anna M. Stagner, Deborah S. Jacobs, Reza Md Dana, Jia Yin

    Purpose: Primary conjunctival molluscum contagiosum (MC) is rare and usually reported in patients with acquired immunodeficiency syndrome. In this study, we present a case of bilateral primary conjunctival MC in a patient with ocular graft-versus-host disease (oGVHD). Methods: This is a case report study. Clinical evaluation, in vivo confocal microscopy imaging, and histopathology were used to confirm the diagnosis. Results: A 38-year-old woman with a history of allogeneic bone marrow transplant and secondary chronic oGVHD presented with ocular discomfort, redness, and dryness. On examination, clusters of white gelatinous nodular lesions, stained with fluorescein and Lissamine green, were observed on the bulbar conjunctiva, along with similar solitary nodular lesions in all quadrants of both eyes. In vivo confocal microscopy revealed nests of epithelial cells with bright inclusions measuring approximately 30–35 μm. Excisional biopsy confirmed the diagnosis of MC. A 6-month post-operative follow-up showed healed conjunctiva with no recurrence and improved ocular comfort. Conclusions: Molluscum contagiosum should be considered in the differential diagnosis of conjunctival lesions in patients with impaired immunity such as oGVHD. In diagnosing MC lesions, in vivo confocal microscopy proves to be valuable. In the absence of topical antiviral treatment, surgical excision is warranted.